TABLE 2.
Patient and envelope protein | t1/2max (min) | b |
---|---|---|
Patient 3501 | ||
pNR104 (pre) | 24.84 ± 2.21 | 9.64 ± 1.98 |
pNR116 (post) | 29.38 ± 1.58 | 12.78 ± 1.43 |
pNR155 (Q40H Q56R) | 40.18 ± 1.50 | 13.76 ± 1.33 |
pNR157 (Q40H Q56R N125D) | 31.91 ± 2.03 | 11.99 ± 1.81 |
Patient 3518 | ||
pNR4 (pre) | 27.46 ± 1.67 | 11.33 ± 1.50 |
pNR13 (post) | 25.12 ± 1.50 | 10.39 ± 1.35 |
pNR76 (N43D Q66R) | 35.74 ± 1.66 | 15.11 ± 1.50 |
pNR79 (N43D Q66R S138A) | 29.94 ± 1.68 | 12.99 ± 1.53 |
The kinetic parameters of cell-cell fusion mediated by HR-1 and HR-2 mutant Envs for patients 3501 and 3518, starting from a TAS, were determined by a β-lactamase reporter assay (Fig. 3). Fusion was assayed from 0 to 100 min in at least three independent experiments, and the data were fitted to the equation Y = Ymax/{1 + exp[−(t − t1/2max)/b]}. pre, pretreatment; post, posttreatment; b, exponential rate constant.